secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0000950170-23-028787
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology amends bylaws and announces annual meeting voting results
----------------------------------------------------------------------

- Board approved amended bylaws effective June 17, 2023, enhancing stockholder nomination procedures and complying with universal proxy rules and Delaware law.
- Three Class III directors elected: Scott Garland (35.7M for), Rekha Hemrajani (31.9M for), Jaume Pons (35.6M for), all to serve until 2026.
- Advisory vote on named executive officer compensation passed (35.5M for, 413K against, 9K abstain).
- Ratification of KPMG as independent auditor for FY2023 approved (38.5M for, 8.8K against, 3K abstain).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/alxo-20230616.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-028787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer